ClinicalTrials.gg
RecruitingNCT05240885Updated Oct 5, 2026

Metabolic and Functional Consequences of Aging in Health and Disease

An observational study in Aging, sponsored by Texas A&M University. Recruiting at 1 site in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Primary conditionnone(registry's first term: Disease)No conditionIs this wrong?Disease describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Texas A&M University · Observational

How we know

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.
Updated Oct 5, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
50 Years and older
Sex
All
01

Study summary

Considerable heterogeneity in the aging population has been observed. The exceptional longevity of individuals reaching 100 years old, so-called centenarians may be an example of life-long healthy aging, or added years may be spent in poor health with decreased physical and cognitive functioning. Current knowledge of the aging experience and the trajectories of physical and cognitive decline across various age groups are not well-understood, yet crucial to prevent spending added years in disease. Hence, the study objective is to develop the metabolic profile associated with aging-related disorders measured as the incidence of impaired functional capacity, cognitive function, and/or well-being.

Read the detailed description

Our lab developed a pulse method combining multiple stable tracers to study multiple metabolic pathways in the same individual simultaneously. By measuring whole-body metabolism in a large group of older adults, we may be able to unravel age-related deterioration in protein turnover (synthesis and breakdown) that contributes to impaired functional capacity. Metabolic profiles could explain differences in pathways in the aging process with a special interest in the metabolism of amino acids as they have been associated with aging-related disorders. Studies on the effect of aging on metabolism might serve as potential therapeutic targets.

02

Conditions studied

  • Aging

Browse trials for

Keywords

  • stable isotopes
  • disease
  • metabolism
03

In context

Lead sponsor

Texas A&M University is the lead sponsor of 124 studies on the registry; 24 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

We will screen 400 subjects (to complete n=320). This number includes screen failures and drop-outs. We expect some dropout between screening and enrollment. Subjects who drop out prior to the successful completion of the study will be replaced. Data will be used up to the point of withdrawal. Age range: 50 years or older, inclusive; Ethnicity: all races and ethnicities.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stable body-weight (± 5%) for the past 3 months
  • Subject is judged to be in satisfactory health based on medical history, physical examination, and laboratory screening evaluations.
  • Ability to walk, sit down and stand up independently or with walking mobility aids
  • Ability to lie in a supine or elevated position for up to 3 hours
  • Discharged within 30 days after a hospital admittance for >48-hours (recently hospitalized group only)
  • Diagnosis of heart failure (stages 2-4 heart failure based on the Functional Class; heart failure group only)
  • Willingness and ability to comply with the protocol

Exclusion criteria

Exclusion Criteria:

  • Insulin dependent diabetes mellitus
  • Established diagnosis of
  • History of untreated metabolic diseases including hepatic or renal disorder
  • Presence of acute illness or metabolically unstable chronic illness
  • Presence of fever within the last 3 days
  • Use of short course of oral within 4 weeks preceding study day
  • Failure to give or Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements
  • (Possible) pregnancy
  • Already enrolled in another clinical trial and that clinical trial interferes with participating in this study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Controls

    Study subjects that are eligible based on inclusion/exclusion criteria Screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Study day(s): may include combinations of stable tracer infusions and with blood draws, cognitive and muscle performance testing

    Other: Stable tracer infusion in a postabsorptive state

Interventions

  • OtherStable tracer infusion in a postabsorptive state

    Multiple stable-labeled tracers of amino acids, ketoacids, glycerol, short-chain fatty acids

    Also known as: Stable tracer infusion

06

What researchers measure

Primary outcomes

  1. Age-related changes in whole-body protein and amino acid metabolism

    Whole-body production rate measured after stable tracer administration

    Time frame: 2 hours

Secondary outcomes

  1. Age-related changes in whole-body glucose metabolism

    Whole-body production rate measured after stable tracer administration

    Time frame: 2 hours

  2. Age-related changes in whole-body fat metabolism

    Whole-body production rate measured after stable tracer administration

    Time frame: 2 hours

  3. Age-related changes in depression as measured by the Hospital Anxiety and Depression Scale (HADS) and Geriatric Depression Scale (if applicable)

    Self-reported depression measured by a validated questionnaire related to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 (no symptoms) and 21 (severe symptoms). A higher score indicates a worse outcome (greater self-reported depression symptoms).

    Time frame: baseline visit

  4. Age-related changes in anxiety as measured by the Hospital Anxiety and Depression Scale (HADS)

    Anxiety measured by a validated questionnaire related to anxiety-related symptoms. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 (no symptoms) and 21 (severe symptoms) related to anxiety. A higher score indicates a worse outcome (greater self-reported anxiety symptoms).

    Time frame: baseline visit

  5. Age-related changes in mood as measured by the Profile of Mood State (POMS)

    A psychological distress scale to measure the mood disturbance in 6 domains - fatigue-inertia, vigor-activity, tension-anxiety, depression-dejection, anger-hostility, and confusion-bewilderment in the past week. Each item on the questionnaire is awarded a score from 0 ("not at all") to 4 ("extremely"), except "Relaxed" and "Efficient" scored 4 ("not at all") and 0 ("extremely"), based on the intensity of the assessed feeling in the past week.

    Time frame: baseline visit

  6. Age-related changes in health status

    Health status assessed by Health-Related Quality of Life Scale (HR-QoL)

    Time frame: baseline visit

  7. Age-related changes in physical activity

    Physical activity assessed by Physical Activity Scale for the Elderly (PASE)

    Time frame: baseline visit

  8. Age-related changes in sleep quality

    Sleep quality assessed by Pittsburgh Sleep Quality Index

    Time frame: baseline visit

  9. Age-related changes in nutritional status

    Nutritional status assessed by Mini-Nutritional Assessment

    Time frame: baseline visit

  10. Age-related changes in attention and executive functions as measured by Trail Making Test (TMT)

    In Part A, the examinee is instructed to connect a set of 25 circles with numbers as quickly as possible while maintaining accuracy. In Part B, the examinee is instructed to connect a set of 25 circles, alternating between numbers and letters, as quickly as possible while maintaining accuracy. Measures attentional resources and is a measure of the frontal lobe "executive" functions of visual search, set-switching and mental flexibility. The total time in seconds was reported for each measure.

    Time frame: baseline visit

  11. Age-related changes in overall cognitive abilities as measured by Montreal Cognitive Assessment (MoCA)

    MoCa assesses several cognitive domains and is used for the screening of mild cognitive impairment. Total scores range from 0-30 with lower scores indicating decreased functioning.

    Time frame: baseline visit

  12. Age-related changes in exercise capacity

    Functional exercise capacity assessed by 6-minute walk test

    Time frame: baseline visit

  13. Age-related changes in physical weakness (frailty)

    Physical weakness assessed by Short Physical Performance Battery

    Time frame: baseline visit

  14. Age-related changes in skeletal muscle strength of the upper extremity

    Skeletal muscle strength measured by handgrip test

    Time frame: baseline visit

  15. Age-related changes in skeletal muscle strength of the lower extremity

    Skeletal muscle strength measured by one-leg test

    Time frame: baseline visit

  16. Age-related changes in respiratory muscle strength

    Respiratory muscle strength measured by a hand-held mouth pressure device (Micro RPM)

    Time frame: baseline visit

  17. Age-related changes in balance

    Skeletal muscle strength measured by Berg Balance Scale and balance platform

    Time frame: baseline visit

  18. Age-related changes in gut microbiota

    The amount and types of microbiota assessed in collected stool sample

    Time frame: baseline visit

  19. Age-related changes in gut function

    Gut function assessed by Gastrointestinal Symptom Rating Scale, a 15-item instrument designed to assess the symptoms associated with common gastrointestinal disorders. A higher score indicates worse outcomes (more discomfort).

    Time frame: baseline visit

Other outcomes

  1. Age-related changes in hand dexterity

    Hand dexterity assessed by the Nine-Hole Peg Test (9-HPT), a standardized, quantitative assessment in which the subject is asked to take pegs from a container, one by one, and place them into the holes on the board. Time upon completion will be recorded using both left and right hand, separately.

    Time frame: baseline visit

07

Study locations

1 of 1 sites recruiting
  • Human Clinical Research Building
    College Station, Texas 77845, United States
    Recruiting
08

References and documents

Publications

  • Huttl VN, Deutz N, Wierzchowska-McNew RA, Ruebush LE, Engelen M. Whole-body and intracellular arginine metabolism in hypertension: role of disease severity and sex. Am J Hypertens. 2026 May 18:hpag047. doi: 10.1093/ajh/hpag047. Online ahead of print. PubMed 42149813 ↗

Individual participant data

Plan to share: Undecided — Data may be shared upon request for up to 6 years beyond completion of the trial based on methods/proposal approved by both parties' institutional review committees. Individual participant data that underlie the results of the trial may be shared after de-identification (text, tables, figures, and appendices). Additional documents available per request include: study protocol, statistical analysis plan, and informed consent. Requests should be directed to Dr. Marielle Engelen (mpkj.engelen@ctral.org).

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2022 (actual). Primary completion is estimated for Sep 2028, 78 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Sep 2026 → Sep 2028 and completion Sep 2026 → Sep 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2022
First posted
Feb 15, 2022
StartActual
Mar 4, 2022
Primary completionEst.
Sep 2028was Sep 2026
CompletionEst.
Sep 2028was Sep 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Sep 2028
Oct 5, 2026
Study completion
Sep 2026→Sep 2028
Oct 5, 2026
Eligibility
2 inclusion criteria added
What changed in the criteria
Inclusion criteria
  • AddedDischarged within 30 days after a hospital admittance for >48-hours (recently hospitalized group only)
  • AddedDiagnosis of heart failure (stages 2-4 heart failure based on the New York Heart Association Functional Class; heart failure group only)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Primary completion Sep 2026→Sep 2028
    Study completion Sep 2026→Sep 2028
    Eligibility 2 inclusion criteria added
    What changed in the criteria
    Inclusion criteria
    • AddedDischarged within 30 days after a hospital admittance for >48-hours (recently hospitalized group only)
    • AddedDiagnosis of heart failure (stages 2-4 heart failure based on the New York Heart Association Functional Class; heart failure group only)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05240885
Responsible party
Marielle PKJ Engelen, PhD (Professor & Chancellor Edges Fellow, Texas A&M University) — Principal investigator
First posted
Feb 15, 2022
Start date
Mar 4, 2022
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Laura Ruebush, PhD
Contact
le.ruebush@ctral.org
979-422-1789
Marielle Engelen, PhD
Contact
mpkj.engelen@ctral.org
979-422-1789

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion